WuXi AppTec's (HKG:2359, SHA:603259) subsidiaries WuXi ATU (Ireland) Holding and WuXi ATU (Hong Kong) agreed to sell all the shares held by them in the WuXi Advanced Therapies and Oxford Genetics to Altaris for cash consideration, a Tuesday Hong Kong bourse filing said.
Altaris is a medical healthcare industry-focused equity investment fund based in the U.S.A., while WuXi Advanced Therapies and Oxford Genetics are U.S. and United Kingdom operating entities of the WuXi ATU business.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.